Cargando…

Na(+)/H(+) Exchanger 1, a Potential Therapeutic Drug Target for Cardiac Hypertrophy and Heart Failure

Cardiac hypertrophy is defined as increased heart mass in response to increased hemodynamic requirements. Long-term cardiac hypertrophy, if not counteracted, will ultimately lead to heart failure. The incidence of heart failure is related to myocardial infarction, which could be salvaged by reperfus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Huiting, Zahra, Aqeela, Jia, Meng, Wang, Qun, Wang, Yunfu, Campbell, Susan L., Wu, Jianping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318128/ https://www.ncbi.nlm.nih.gov/pubmed/35890170 http://dx.doi.org/10.3390/ph15070875

Ejemplares similares

Understanding the Physiological Role of Electroneutral Na(+)-Coupled HCO(3)(−) Cotransporter and Its Therapeutic Implications
por: Wang, Jingjing, et al.
Publicado: (2022)

K(Ca)-Related Neurological Disorders: Phenotypic Spectrum and Therapeutic Indications
por: Zahra, Aqeela, et al.
Publicado: (2023)

Shared Etiology in Autism Spectrum Disorder and Epilepsy with Functional Disability
por: Zahra, Aqeela, et al.
Publicado: (2022)

Glucose Metabolism in Cardiac Hypertrophy and Heart Failure
por: Tran, Diem H., et al.
Publicado: (2019)

Epigenetics in Cardiac Hypertrophy and Heart Failure
por: Liu, Chia-Feng, et al.
Publicado: (2019)

Noncoding RNAs in Cardiac Hypertrophy and Heart Failure
por: Lu, Peilei, et al.
Publicado: (2022)

CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure
por: Zhang, Yang, et al.
Publicado: (2022)

Role of Irisin in Myocardial Infarction, Heart Failure, and Cardiac Hypertrophy
por: Ho, Ming-Yun, et al.
Publicado: (2021)

β-AR Blockers Suppresses ER Stress in Cardiac Hypertrophy and Heart Failure
por: Ni, Li, et al.
Publicado: (2011)

Cardiac‐specific ablation of glutaredoxin 3 leads to cardiac hypertrophy and heart failure
por: Donelson, Jimmonique, et al.
Publicado: (2019)

The effect of inhibition of the Na(+)/H(+) exchanger on the development of hypertrophy in hypertrophic cardiomyopathy
por: Brouwer, Wessel P, et al.
Publicado: (2011)

Inhalation of diesel exhaust does not exacerbate cardiac hypertrophy or heart failure in two mouse models of cardiac hypertrophy
por: Liu, Yonggang, et al.
Publicado: (2013)

Angiogenic Endothelial Cell Signaling in Cardiac Hypertrophy and Heart Failure
por: Gogiraju, Rajinikanth, et al.
Publicado: (2019)

Roles of histone acetylation sites in cardiac hypertrophy and heart failure
por: Funamoto, Masafumi, et al.
Publicado: (2023)

Understanding the Functional Expression of [Formula: see text]-Coupled SLC4 Transporters in the Renal and Nervous Systems: A Review
por: Du, Le, et al.
Publicado: (2021)

Double-edged Role of K(Na) Channels in Brain Tuning: Identifying Epileptogenic Network Micro-Macro Disconnection
por: Liu, Ru, et al.
Publicado: (2022)

Transcription Factors in Heart: Promising Therapeutic Targets in Cardiac Hypertrophy
por: Kohli, Shrey, et al.
Publicado: (2011)

A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure
por: Wang, Zhenya, et al.
Publicado: (2023)

Brain Renin–Angiotensin System in Hypertension, Cardiac Hypertrophy, and Heart Failure
por: Campos, Luciana Aparecida, et al.
Publicado: (2012)

A personalized, multiomics approach identifies genes involved in cardiac hypertrophy and heart failure
por: Santolini, Marc, et al.
Publicado: (2018)

Na(+)/H(+) Exchanger Isoform 1-Induced Osteopontin Expression Facilitates Cardiomyocyte Hypertrophy
por: Mohamed, Iman A., et al.
Publicado: (2015)

Na(+)/Ca(2+) exchange and Na(+)/K(+)-ATPase in the heart
por: Shattock, Michael J, et al.
Publicado: (2015)

Aberrant Glycosylation in the Left Ventricle and Plasma of Rats with Cardiac Hypertrophy and Heart Failure
por: Nagai-Okatani, Chiaki, et al.
Publicado: (2016)

Early dystrophin loss is coincident with the transition of compensated cardiac hypertrophy to heart failure
por: Prado, Fernanda P., et al.
Publicado: (2017)

Oxidative Stress as A Mechanism for Functional Alterations in Cardiac Hypertrophy and Heart Failure
por: Shah, Anureet K., et al.
Publicado: (2021)

Echocardiographic markers of cardiac amyloidosis in patients with heart failure and left ventricular hypertrophy
por: Polo, Jorge Melero, et al.
Publicado: (2023)

Impact of polyphenols on heart failure and cardiac hypertrophy: clinical effects and molecular mechanisms
por: Hedayati, Neda, et al.
Publicado: (2023)

KLF2 regulates neutrophil activation and thrombosis in cardiac hypertrophy and heart failure progression
por: Tang, Xinmiao, et al.
Publicado: (2022)

Na/Ca exchange in the intact cardiac cell
Publicado: (1985)

Heart-targeting exosomes from human cardiosphere-derived cells improve the therapeutic effect on cardiac hypertrophy
por: Mao, Liang, et al.
Publicado: (2022)

Cardiac ISL1-Interacting Protein, a Cardioprotective Factor, Inhibits the Transition From Cardiac Hypertrophy to Heart Failure
por: Yan, Youchen, et al.
Publicado: (2022)

Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure
por: Funayama, Akira, et al.
Publicado: (2013)

Loss of Akap1 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure
por: Schiattarella, Gabriele G., et al.
Publicado: (2018)

Role and mechanism of cardiac insulin resistance in occurrence of heart failure caused by myocardial hypertrophy
por: Zheng, Liling, et al.
Publicado: (2019)

Protective Effects of Thyroid Hormone Deprivation on Progression of Maladaptive Cardiac Hypertrophy and Heart Failure
por: Kerp, Helena, et al.
Publicado: (2021)

Increased sarcolemmal Na(+)/H(+) exchange activity in hypertrophied myocytes from dogs with chronic atrioventricular block
por: van Borren, Marcel M. G. J., et al.
Publicado: (2013)

Gentisic acid prevents the transition from pressure overload-induced cardiac hypertrophy to heart failure
por: Sun, Simei, et al.
Publicado: (2019)

AAV-mediated expression of NFAT decoy oligonucleotides protects from cardiac hypertrophy and heart failure
por: Remes, Anca, et al.
Publicado: (2021)

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
por: Han, Yu, et al.
Publicado: (2022)

KR-39038, a Novel GRK5 Inhibitor, Attenuates Cardiac Hypertrophy and Improves Cardiac Function in Heart Failure
por: Lee, Jeong Hyun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sf8hf3do14g4h2gtbct1a0ri19